The present disclosure provides nanoemulsion formulations for increasing the bioavailability and efficacy of the Halofantrine. Particularly, it relates to the oral and parenteral nanoemulsion formulations for Halofantrine or its pharmaceutically acceptable •salts/enantiomers thereof for the treatment and/or prophylaxis of malaria. The nanoemulsion formulation of the present disclosure has high bioavailability and hence shows improved efficacy and reduced cardiotoxieity as compared to the existing Halofantrine formulations.
